HaluGen is a Vancouver-based healthcare technology company with the goal of helping people make informed choices around psychedelic-assisted therapy through personalization. Through its proprietary pre-screening platform, users can gain rapid genetic insights from a simple cheek swab. On January 14th, 2021, HaluGen was acquired by Entheon Biomedical. The terms of the transaction were not disclosed.
Expert Collections containing HaluGen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
HaluGen is included in 1 Expert Collection, including Psychedelics.
Latest HaluGen News
Jun 1, 2022
MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision medicine to improve patient outcomes through its partnership with Entheon Biomedical Corp.’s (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon") wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”) to use its psychedelics genetic test kit. KetaDASH will become one of the first psychedelic companies to use precision medicine to test patients by using HaluGen’s expanded psychedelics genetic testing panel, which analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual's risk and potential of adverse reactions with the use of ketamine.
HaluGen Frequently Asked Questions (FAQ)
Where is HaluGen's headquarters?
HaluGen's headquarters is located at 595 Howe St, Vancouver.
What is HaluGen's latest funding round?
HaluGen's latest funding round is Acquired.
Who are the investors of HaluGen?
Investors of HaluGen include Entheon Biomedical.